US 11,701,433 B2
Complexes for delivery of antigenic peptides
Yu Lei, Ann Arbor, MI (US); Yee Sun Tan, Ann Arbor, MI (US); Kanokwan Sansanaphongpricha, Ann Arbor, MI (US); Duxin Sun, Ann Arbor, MI (US); Hongwei Chen, Ann Arbor, MI (US); and Hongxiang Hu, Ann Arbor, MI (US)
Assigned to The Regents of the University of Michigan, Ann Arbor, MI (US)
Appl. No. 16/619,802
Filed by The Regents of the University of Michigan, Ann Arbor, MI (US)
PCT Filed Jun. 1, 2018, PCT No. PCT/US2018/035623
§ 371(c)(1), (2) Date Dec. 5, 2019,
PCT Pub. No. WO2018/226529, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/515,234, filed on Jun. 5, 2017.
Prior Publication US 2020/0129640 A1, Apr. 30, 2020
Int. Cl. A61K 9/00 (2006.01); A61K 47/69 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/118 (2006.01); A61K 39/385 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 47/6929 (2017.08) [A61K 39/0003 (2013.01); A61K 39/0011 (2013.01); A61K 39/02 (2013.01); A61K 39/118 (2013.01); A61K 39/385 (2013.01); A61K 47/643 (2017.08); A61K 47/646 (2017.08); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); A61K 2039/55561 (2013.01); A61K 2039/572 (2013.01); A61K 2039/60 (2013.01); A61K 2039/622 (2013.01); B82Y 5/00 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating head and neck squamous cell carcinoma (HNSCC) in a subject comprising: administering to a subject having at least one HNSCC tumor:
a) a composition comprising a nano-satellite complex, wherein said nano-satellite complex comprises:
i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core;
ii) at least one satellite particle attached to, or absorbed to, said biocompatible coating;
iii) an antigenic component conjugated to, or absorbed to, said at least one satellite particle component, wherein said antigenic component comprises an antigenic peptide, wherein said antigenic peptide comprises at least one epitope from a viral oncoprotein; and
iv) a type I interferon agonist agent which is electrostatically attracted to, or absorbed to, said antigenic component; and
b) an immune checkpoint inhibitor.